Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women

Journal of Bone and Mineral Research

Volumn 13, Issue 6, 1998, Pages 1051-1055

  Cosman, Felicia ^a,b   Nieves, Jeri ^a,b   Woelfert, Lillian ^a   Shen, Victor ^a,b   Lindsay, Robert ^a,b  

^a HELEN HAYES HOSPITAL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; CALCIUM; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; PROCOLLAGEN; PYRIDINOLINE; TILUDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CLINICAL ARTICLE; FEMALE; HORMONE ACTION; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION; URINARY EXCRETION; VITAMIN BLOOD LEVEL;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; AMINO ACIDS; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DRUG SYNERGISM; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PILOT PROJECTS; PROCOLLAGEN; TERIPARATIDE;

EID: 0031802037     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.6.1051     Document Type: Article

References (27)

1. Fleisch H 1996 Bisphosphonates: Mechanisms of action and clinical use. In: Bilezikian JP, Raisz LG, Rodan GA (eds.) Principles of Bone Biology. Academic Press, San Diego, CA, U.S.A., pp. 1037-1052.
2. Lindsay R, Cosman F 1996 The pharmacology of estrogens in osteoporosis. In: Bilezikian JP, Raisz LG, Rodan GA (eds.) Principles of Bone Biology. Academic Press, San Diego, CA, U.S.A., pp. 1063-1068.
3. Azria M, Avioli LV 1996 Calcitonin. In: Bilezikian JP, Raisz LG, Rodan GA (eds.) Principles of Bone Biology. Academic Press, San Diego, CA, U.S.A., pp. 1083-1098.
4. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
5. Lindsay R 1995 Estrogen deficiency. In: Riggs BL (ed.) Osteoporosis: Etiology, Diagnosis and Management, 2nd Ed. Lippincott-Raven, Philadelphia, PA, U.S.A., pp. 133-160.
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
7. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709.
8. Reeve J, Arlot M, Bernt M, Charhon S, Edouard C, Slovik D, Vismans FJFE, Meunier PJ 1981 Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: The influence of human parathyroid fragment (hPTH 1-34) therapy. Metab Bone Dis Rel Res 3:23-30.
9. Hesp R, Hulme P, Williams D, Reeve J 1981 The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment hPTH(1-34). Metab Bone Dis Rel Res 2:331-334.
10. Shen V, Birchman R, Xu R, Otter M, Wu D, Lindsay R, Dempster DW 1995 Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone 65: Structure and strength in ovariectomized rats. J Clin Invest 96:2331-2338.
11. Mosekilde L, Danielson CC, Gasser J 1994 The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone (1-38), and combination therapy, assess in aged ovariectomized rats. Endocrinology 134:2126-2134.
12. Li M, Mosekilde L, Sogaard CH, Thomsen JS, Wronski TJ 1995 Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 16:629-635.
13. Hock JM, Hummert JR, Boyce R, Fonseca J, Raisz LG 1989 Resorption is not essential for the stimulation of bone growth by hPTH(1-34) in rats in vivo. J Bone Miner Res 4:449-458.
14. Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ 1994 PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate)-assessed in sexually mature, ovariectomized rats. Bone 15:401-408.
15. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MHL 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption in inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610.
16. Mosekilde L, Thomsen JS, Kneissel M, Gasser JA 1997 Alendronate blunts the anabolic effect of a PTH analog, SDZ PTS 893, when administered sequentially. J Bone Miner Res 12 (Suppl 1):S343 (abstract F470).
17. Preece MAA, O'Riordan JLH, Lawson DEM, Kodicek E 1974 An assay for 25-dihydroxycholecaciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta 54:235-242.
18. Reinhardt TA, Horst R, Orf JW, Hollis BW 1984 A microassay for dihydroxyvitamin D not requiring HPLC: Application to clinical studies. J Clin Endocrinol Metab 58:91-98.
19. Hanson DA, Weis ME, Bollen AM, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptide in urine. J Bone Miner Res 7:1251-1258.
20. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F 1993 Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 8:643-648.
21. Cosman F, Shen V, Herrington B, Lindsay R 1991 Response of the parathyroid gland to infusion of (1-34) hPTH: Demonstration of suppression of endogenous secretion using IRMA intack (1-84) PTH assay. J Clin Endocrinol Metabol 73:1345-1351.
22. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, Lindsay R, Parisien M 1997 Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 12:958-966.
23. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster DW, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebralbone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
24. Frost HM 1979 Treatment of osteoporosis by manipulation of coherent cell populations. Clin Orthop 143:227-244.
25. Frost HM 1984 The ADFR concept revisited. Calcif Tissue Int 36:349-353.
26. Hodsman AB 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surface. Bone 14:523-527.
27. Eriksen EF, Brixen K, Charles P 1995 New markers of bone metabolism: Clinical use in metabolic bone disease. Eur J Endocrinol 132:251-263.